L1CAM as a Negative Prognostic Factor in Endometrioid
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA21025OV" target="_blank" >RIV/61988987:17110/19:A21025OV - isvavai.cz</a>
Výsledek na webu
<a href="http://ar.iiarjournals.org/content/39/1/421" target="_blank" >http://ar.iiarjournals.org/content/39/1/421</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.13128" target="_blank" >10.21873/anticanres.13128</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
L1CAM as a Negative Prognostic Factor in Endometrioid
Popis výsledku v původním jazyce
Aims: In this study, we aimed to investigate how positivity for L1 cell adhesion molecule (L1CAM) was associated with outcome and relapse pattern in patients with Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage IA-IB endometrial cancer. Materials and Methods: This retrospective study included 358 patients who underwent surgical treatment for endometrial carcinoma. Tumor samples from 312 patients (87.2%) were available for L1CAM analysis by immunohistochemistry. Results: Of the 312 tumor samples analyzed, 93 (29.8%) were L1CAM-positive. L1CAM positivity was significantly more common in grade 3 compared to grade 1-2 carcinomas (p=0.02). Patients with L1CAM positivity more commonly experienced disease progression. Distant metastasis was significantly associated with L1CAM positivity (p=0.01). Progression-free interval and overall survival did not significantly differ between L1CAM-positive and L1CAM-negative cases. Conclusion: L1CAM is a promising independent prognostic marker associated with aggressive tumor behavior and recurrence risk, but not with overall survival.
Název v anglickém jazyce
L1CAM as a Negative Prognostic Factor in Endometrioid
Popis výsledku anglicky
Aims: In this study, we aimed to investigate how positivity for L1 cell adhesion molecule (L1CAM) was associated with outcome and relapse pattern in patients with Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage IA-IB endometrial cancer. Materials and Methods: This retrospective study included 358 patients who underwent surgical treatment for endometrial carcinoma. Tumor samples from 312 patients (87.2%) were available for L1CAM analysis by immunohistochemistry. Results: Of the 312 tumor samples analyzed, 93 (29.8%) were L1CAM-positive. L1CAM positivity was significantly more common in grade 3 compared to grade 1-2 carcinomas (p=0.02). Patients with L1CAM positivity more commonly experienced disease progression. Distant metastasis was significantly associated with L1CAM positivity (p=0.01). Progression-free interval and overall survival did not significantly differ between L1CAM-positive and L1CAM-negative cases. Conclusion: L1CAM is a promising independent prognostic marker associated with aggressive tumor behavior and recurrence risk, but not with overall survival.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
ANTICANCER RESEARCH
ISSN
0250-7005
e-ISSN
1791-7530
Svazek periodika
39
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
GR - Řecká republika
Počet stran výsledku
3
Strana od-do
421-424
Kód UT WoS článku
000454413400055
EID výsledku v databázi Scopus
—